|
|
Article: NexMed to Initiate 400 Femprox(R) Clinical Study in China For Female Sexual Arousal Disorder (FSAD); - Company to Report 2003 Results on Thursday, March 4 -.
- Article from:
- PR Newswire
- Article date:
- March 2, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NexMed, Inc. , a developer of innovative transdermal treatments based on its proprietary drug delivery technology, today announced its plans to initiate a 400-patient Phase 3 study for Femprox(R) in China. The design of this study is based on results from NexMed's clinical studies to date, and is double-blind, placebo-controlled and randomized, and will test the efficacy and safety of Femprox(R) cream in patients diagnosed with female sexual arousal disorder (FSAD).
Femprox(R), recently profiled on CBS 20/20 television program, is topically applied, and incorporates alprostadil, a vasodilator that is administered through the NexACT(R) transdermal enhancer. In ...